Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Profit Projections Are Still Plunging for the 3 Most Popular Pot Stocks

By Sean Williams - Jun 19, 2019 at 6:36AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Marijuana may not have investors seeing much green through 2020.

Legal marijuana projects as one of the fastest-growing industries for the next couple of years. It generated $12.2 billion in global sales in 2018, and the team of Arcview Market Research and BDS Analytics have forecast worldwide revenue of $31.3 billion by 2022. This works out to a compound annual growth rate of 26.6% over the next four years.

Yet, despite this growth, we witnessed a strange occurrence during the first few months of 2019. Namely, profit projections (or loss estimates for some marijuana stocks) for the following year, fiscal 2020, have been worsening. While it's not uncommon for Wall Street's consensus estimates to be all over the place for nascent but fast-growing industries, the expectation had been that this decline in 2020 profit projections would ebb after a few months. Unfortunately, that's not been the case.

A small pile of $100 bills on fire, with $100 bills as wallpaper in the background.

Image source: Getty Images.

Marijuana's most popular stocks are turning into fundamental nightmares

A quick examination of the three most popular pot stocks -- Canopy Growth ( CGC 1.50% ), Aurora Cannabis ( ACB 2.19% ), and Cronos Group ( CRON 3.37% ) -- reveals that Wall Street's fiscal 2020 consensus estimate for these companies continues to plunge.

Three months ago, Canopy Growth, Aurora Cannabis, and Cronos Group were respectively expected to deliver (all figures in Canadian dollars) a loss of CA$0.24, a profit of CA$0.03, and a profit of CA$0.16 in fiscal 2020. But as of this past weekend, those estimates had plunged to a consensus loss of CA$0.42 for Canopy, a loss of CA$0.06 for Aurora, and a mere CA$0.04 profit for Cronos. At the rate things have progressed, all three may lose money in 2020 after pretty much every pundit called for healthy profits by 2020 for a vast majority of marijuana stocks.

This is a problem, given that earnings results actually matter now. With Canada having legalized recreational marijuana in October, more than 40 countries in the world now allowing some form of medical cannabis use, and a fifth of the U.S. market soon allowing adult-use weed sales (once Illinois kicks off sales on Jan. 1, 2020), marijuana stocks no longer have any excuses to mask their premium valuations. As a result, we've seen a number of high-profile pot stocks, including Canopy, Aurora, and Cronos, taken to the proverbial woodshed in the second quarter.

A cannabis leaf lying within the outline of the Canadian flag red maple leaf, along with with rolled joints and a cannabis bud to the left of the flag.

Image source: Getty Images.

Here's why profit projections keep falling

What's to blame, you ask?

Part of the problem rests with regulatory red tape to our north. Regulatory agency Health Canada has been contending with a backlog of more than 800 applications, many of which are for cultivation. The agency recently announced a change that will require growers to complete production facilities prior to submitting a cultivation license application. This should remove underfunded growers from the application backlog and potentially expedite a process that can take months, or even more than a year, in some cases, to complete. Perhaps in 12 months, or a bit longer, this cultivation application backlog will be no more. Unfortunately, the sales license application backlog is another story altogether.

Canada has also been contending with a shortage of compliant packaging solutions. Health Canada laid out a laundry list of regulations that growers would need to abide by if they want their product to make it onto dispensary store shelves. This demanding list has kept a lot of cannabis sitting on the sidelines for the time being.

But you can also place some of the blame on the growers themselves. For starters, growers weren't exactly willing to boost production well in advance of the Cannabis Act becoming law. Since capacity expansion is costly, companies like Canopy, Aurora, and Cronos waited until very late 2017 or early 2018 before really getting to work on production expansion. This relatively late start has left many operating at nowhere near their peak capacity.

A visibly frustrated stock trader grasping the top of his head while looking at multiple computer monitors.

Image source: Getty Images.

These aforementioned popular pot stocks haven't exactly been putting their shareholders first, either. In order to facilitate their expansion, these companies have been issuing shares of their stock like it's going out of style. Although these share issuances have successfully raised needed capital, a ballooning outstanding share count has a tendency to weigh on profits, since it means net income is divided into a greater number of sharers. Between Aurora issuing roughly 1 billion shares in less than five years, and both Canopy and Cronos ballooning their share counts through bought-deal offerings and somewhat recent equity investments, these companies aren't exactly putting themselves in the best position to grow their bottom lines right now.

Long story short, sales are expected to rise significantly for Canopy, Aurora, and Cronos, but nothing suggests that they'll be ready to turn the corner to recurring profitability before the end of 2020. That makes these three popular pot stocks potentially risky investments.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Canopy Growth Stock Quote
Canopy Growth
$10.14 (1.50%) $0.15
Aurora Cannabis Stock Quote
Aurora Cannabis
$5.95 (2.19%) $0.13
Cronos Group Stock Quote
Cronos Group
$4.30 (3.37%) $0.14

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/06/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.